Epigral Ltd
Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure.
In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC Resin. Epigral is also a leading manufacturer of Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine and Hydrogen.
- Market Cap ₹ 7,498 Cr.
- Current Price ₹ 1,738
- High / Low ₹ 2,408 / 940
- Stock P/E 21.6
- Book Value ₹ 324
- Dividend Yield 0.29 %
- ROCE 17.5 %
- ROE 16.9 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 30.2%
Cons
- Promoter holding has decreased over last quarter: -2.64%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Chemicals Industry: Chemicals
Part of BSE Commodities Nifty Microcap 250 BSE SmallCap BSE Allcap Nifty Total Market
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
394 | 392 | 598 | 710 | 611 | 829 | 1,551 | 2,188 | 1,929 | 2,447 | |
245 | 248 | 346 | 405 | 416 | 567 | 1,041 | 1,499 | 1,448 | 1,754 | |
Operating Profit | 149 | 144 | 252 | 306 | 194 | 261 | 510 | 689 | 481 | 693 |
OPM % | 38% | 37% | 42% | 43% | 32% | 32% | 33% | 31% | 25% | 28% |
2 | 1 | 8 | 16 | 2 | 2 | 4 | 8 | 6 | 13 | |
Interest | 19 | 14 | 9 | 25 | 11 | 29 | 44 | 66 | 73 | 55 |
Depreciation | 44 | 55 | 55 | 54 | 44 | 74 | 86 | 109 | 124 | 129 |
Profit before tax | 88 | 75 | 195 | 242 | 141 | 161 | 383 | 523 | 291 | 522 |
Tax % | 23% | 11% | 20% | 25% | 21% | 37% | 34% | 32% | 33% | |
67 | 67 | 155 | 183 | 112 | 101 | 253 | 353 | 196 | 347 | |
EPS in Rs | 9.49 | 9.40 | 21.97 | 44.38 | 27.19 | 24.48 | 60.84 | 85.04 | 47.12 | 82.53 |
Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 6% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 22% |
3 Years: | 33% |
TTM: | 24% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 2% |
3 Years: | 25% |
TTM: | 77% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 29% |
1 Year: | 42% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 30% |
3 Years: | 30% |
Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 71 | 71 | 71 | 41 | 42 | 42 | 42 | 42 | 42 | 42 |
Reserves | 224 | 291 | 447 | 241 | 331 | 432 | 684 | 1,028 | 1,213 | 1,358 |
190 | 123 | 74 | 601 | 737 | 753 | 993 | 879 | 964 | 904 | |
55 | 42 | 79 | 162 | 164 | 223 | 405 | 484 | 576 | 676 | |
Total Liabilities | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 2,979 |
364 | 398 | 347 | 295 | 440 | 1,102 | 1,068 | 1,804 | 1,767 | 1,912 | |
CWIP | 69 | 3 | 79 | 468 | 691 | 126 | 589 | 158 | 483 | 350 |
Investments | -0 | 29 | 71 | -0 | -0 | 0 | 0 | 21 | 21 | 21 |
106 | 98 | 173 | 281 | 142 | 221 | 467 | 449 | 524 | 696 | |
Total Assets | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 2,979 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
165 | 229 | 284 | 626 | 398 | |||||
-363 | -197 | -455 | -437 | -401 | |||||
69 | -32 | 195 | -200 | -8 | |||||
Net Cash Flow | -129 | 1 | 24 | -11 | -11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 43 | 41 | 47 | 40 | 46 | 52 | 60 | 28 | 34 |
Inventory Days | 75 | 59 | 45 | 58 | 64 | 51 | 74 | 69 | 90 |
Days Payable | 31 | 37 | 51 | 52 | 62 | 69 | 42 | 36 | 57 |
Cash Conversion Cycle | 86 | 63 | 42 | 46 | 48 | 34 | 92 | 61 | 67 |
Working Capital Days | 43 | 40 | 19 | -26 | -65 | -59 | 26 | 15 | 25 |
ROCE % | 18% | 37% | 36% | 15% | 16% | 29% | 32% | 17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
6 Feb - The Company is participating in Nuvama India Conference 2025 scheduled on 12th February, 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
31 Jan - Intimation of One on One VC meetings on February 3, 2025.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
30 Jan - Transcript of Q3 FY25 earnings conference call.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 Jan - Epigral Limited submits copy of Newspaper Publication in respect of Record Date for the purpose of payment of Interim Dividend for F. Y. 2024-25
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 Jan - Epigral Limited submits copy of Newspaper Advertisement of Un-Audited Financial Results for the third quarter and nine months ended 31.12.2024.
Annual reports
Concalls
-
Jan 2025Transcript PPT REC
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
Apr 2024Transcript PPT
-
Apr 2024Transcript PPT REC
-
Apr 2024TranscriptNotesPPT
-
Jan 2024TranscriptPPT
-
Jan 2024Transcript PPT REC
-
Jan 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
Apr 2023Transcript PPT REC
-
Jan 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptNotesPPT
-
Jun 2022TranscriptNotesPPT
-
Apr 2022Transcript PPT
-
Apr 2022TranscriptNotesPPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Nov 2021TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
Product Segments
a. Derivatives & Speciality Chemicals (56% in H1 FY25 vs 25% in FY22): [1] [2] The company is the 5th largest producer of Chloromethanes (CMS) in India, its CMS portfolio includes MDC, Chloroform and CTC. It is also 3rd largest producer of Hydrogen Peroxide in India. [3] It also produces specialty chemicals like CPVC Resin, CPVC compound, Epichlorohydrin, Chlorotoluenes Value Chain, etc. [4]